55 related articles for article (PubMed ID: 7591889)
1. Correlation of survival with quantitative tissue staining of prostate specific acid phosphatase in patients with prostate carcinoma by using microscopic image analysis: a preliminary report of correlative studies on RTOG protocols 75-06, 77-06, and 83-07.
Zhou R; Sause WT; Hammond EH; Rubin P; Perez C; Pilepich MV; Asbell SD; Parker DL
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):823-9. PubMed ID: 7591889
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of prostate-specific acid phosphatase in prostate cancer: reproducibility and correlation with subjective grade.
Zhou R; Hammond EH; Sause WT; Rubin P; Emami B; Pilepich MV; Asbell SD; Parker DL
Mod Pathol; 1994 May; 7(4):440-8. PubMed ID: 7520585
[TBL] [Abstract][Full Text] [Related]
3. Quantitative peroxidase-antiperoxidase complex-substrate mass determination in tissue sections by a dual wavelength method.
Zhou R; Parker DL; Hammond EH
Anal Quant Cytol Histol; 1992 Apr; 14(2):73-80. PubMed ID: 1590900
[TBL] [Abstract][Full Text] [Related]
4. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical acid phosphatase level and tumor grade in prostatic carcinoma.
Bentz MS; Cohen C; Demers LM; Budgeon LR
Arch Pathol Lab Med; 1982 Sep; 106(9):476-80. PubMed ID: 6287961
[TBL] [Abstract][Full Text] [Related]
6. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
7. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma.
Takeda H; Akakura K; Masai M; Akimoto S; Yatani R; Shimazaki J
Cancer; 1996 Mar; 77(5):934-40. PubMed ID: 8608487
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
Cowen D; Troncoso P; Khoo VS; Zagars GK; von Eschenbach AC; Meistrich ML; Pollack A
Clin Cancer Res; 2002 May; 8(5):1148-54. PubMed ID: 12006531
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Cancer; 2003 Feb; 97(4):979-83. PubMed ID: 12569596
[TBL] [Abstract][Full Text] [Related]
12. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
13. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
14. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
Pilepich MV; Winter K; Lawton CA; Krisch RE; Wolkov HB; Movsas B; Hug EB; Asbell SO; Grignon D
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1285-90. PubMed ID: 15817329
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
[TBL] [Abstract][Full Text] [Related]
16. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
17. PSP94 expression after androgen deprivation therapy: a comparative study with prostate specific antigen in benign prostate and prostate cancer.
Imasato Y; Xuan JW; Sakai H; Izawa JI; Saito Y; Chin JL; Moussa M
J Urol; 2000 Nov; 164(5):1819-24. PubMed ID: 11025776
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
Ludgate CM; Bishop DC; Pai H; Eldridge B; Lim J; Berthelet E; Blood P; Piercy GB; Steinhoff G
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1309-15. PubMed ID: 16029786
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
20. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
